These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24861358)

  • 21. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The evolving role of biologics in the treatment of pediatric psoriasis.
    Luu M; Cordoro KM
    Skin Therapy Lett; 2013 Feb; 18(2):1-4. PubMed ID: 23508772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting.
    de Korte J; van der Valk PG; Sprangers MA; Damstra RJ; Kunkeler AC; Lijnen RL; Oranje AP; de Rie MA; de Waard-van der Spek FB; Hol CW; van de Kerkhof PC
    Br J Dermatol; 2008 Feb; 158(2):375-81. PubMed ID: 18067483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.
    Mrowietz U; Kragballe K; Reich K; Griffiths CE; Gu Y; Wang Y; Rozzo SJ
    Br J Dermatol; 2013 Feb; 168(2):374-80. PubMed ID: 22880843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis].
    Vañó-Galván S; Gárate MT; Fleta-Asín B; Hidalgo A; Fernández-Guarino M; Bermejo T; Jaén P
    Actas Dermosifiliogr; 2012 Mar; 103(2):127-37. PubMed ID: 22036021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network.
    van den Reek JM; van Lüumig PP; Otero ME; Zweegers J; van de Kerkhof PC; Ossenkoppele PM; Njoo MD; Mommers JM; Koetsier MI; Arnold WP; Sybrandy-Fleuren BA; Kuijpers AL; Andriessen MP; Seyger MM; Kievit W; de Jong EM
    Br J Dermatol; 2014 May; 170(5):1158-65. PubMed ID: 24484403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A scientific debate: key clinical questions in the management of psoriasis.
    Stingl G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():1. PubMed ID: 22758910
    [No Abstract]   [Full Text] [Related]  

  • 28. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
    Rallis E; Verros CD
    Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
    [No Abstract]   [Full Text] [Related]  

  • 29. [Psoriasis updates].
    Boulinguez S
    Ann Dermatol Venereol; 2010 May; 137(5 Suppl 1):1-4. PubMed ID: 20510173
    [No Abstract]   [Full Text] [Related]  

  • 30. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
    Moreno-Ramírez D
    Actas Dermosifiliogr; 2011 May; 102(4):241-3. PubMed ID: 21481332
    [No Abstract]   [Full Text] [Related]  

  • 31. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
    Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
    J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy of etanercept for psoriasis in daily practice.
    Van Lümig PP; Driessen RJ; Boezeman JB; Van De Kerkhof PC; De Jong EM
    Br J Dermatol; 2012 Feb; 166(2):445-7. PubMed ID: 21910699
    [No Abstract]   [Full Text] [Related]  

  • 33. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor necrosis factor antagonists in the therapy of psoriasis.
    Mössner R; Schön MP; Reich K
    Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis.
    Menting SP; Sitaram AS; Bonnerjee-van der Stok HM; de Rie MA; Hooft L; Spuls PI
    Br J Dermatol; 2014 Oct; 171(4):875-83. PubMed ID: 24673245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
    Wu JJ; Poon KY; Bebchuk JD
    J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New treatments for psoriasis: which biologic is best?
    Nelson AA; Pearce DJ; Fleischer AB; Balkrishnan R; Feldman SR
    J Dermatolog Treat; 2006; 17(2):96-107. PubMed ID: 16766334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
    Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
    Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy.
    Gisondi P; Pezzolo E; Lo Cascio G; Girolomoni G
    Br J Dermatol; 2014 Oct; 171(4):884-90. PubMed ID: 24863903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.